Reviewing How Second Primary Cancer Risk Factors Into CAR T-Cell Therapy Considerations

Optimized T-cell manufacturing is one strategy that may prevent SPCs after CAR T-cell therapy, according to Shyam A. Patel, MD, PhD, and Saurabh Dahiya, MD, FACP.

Shyam A. Patel, MD, PhD, discusses secondary prevention strategies that may mitigate the risk of developing SPCs after receipt of CAR T-cell therapy.

Saurabh Dahiya, MD, FACP, details the pathobiology of second primary cancers following receipt of CAR T-cell therapy for hematologic malignancies.

Shyam A. Patel, MD, PhD, and Saurabh Dahiya, MD, FACP, detail the pathobiology of SPCs after CAR T-cell therapy and findings from a review on the cancers.

Drs Dahiya and Patel discuss how SPC research may help optimize CAR T-cell product development in the future.

CAR T-cell therapies are associated with a risk for second primary cancers, and mitigation strategies for these toxic effects are warranted and under examination.